DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · IEX Real-Time Price · USD
0.665
-0.025 (-3.62%)
May 2, 2024, 11:51 AM EDT - Market open
DBV Technologies Revenue
In the year 2023, DBV Technologies had annual revenue of $15.73M with 224.69% growth. Revenue in the quarter ending December 31, 2023 was $8.88M, a -780.60% decrease year-over-year.
Revenue (ttm)
$15.73M
Revenue Growth
+224.69%
P/S Ratio
8.44
Revenue / Employee
$151,231
Employees
104
Market Cap
129.04M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
Dec 31, 2019 | 14.71M | -1.57M | -9.66% |
Dec 31, 2018 | 16.28M | 2.94M | 22.07% |
Dec 31, 2017 | 13.34M | 3.16M | 31.10% |
Dec 31, 2016 | 10.17M | 3.27M | 47.32% |
Dec 31, 2015 | 6.91M | 1.57M | 29.48% |
Dec 31, 2014 | 5.33M | 1.05M | 24.46% |
Dec 31, 2013 | 4.29M | 1.18M | 37.80% |
Dec 31, 2012 | 3.11M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amylyx Pharmaceuticals | 380.79M |
So-Young International | 211.29M |
Karyopharm Therapeutics | 146.03M |
Outset Medical | 130.38M |
Repare Therapeutics | 51.13M |
Zomedica | 25.19M |
MSP Recovery | 7.71M |
Sagimet Biosciences | 2.00M |
DBVT News
- 6 days ago - Combined General Meeting of May 16, 2024 - GlobeNewsWire
- 7 weeks ago - DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document - GlobeNewsWire
- 7 weeks ago - DBV Technologies Reports Full Year 2023 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 - GlobeNewsWire
- 2 months ago - DBV Technologies to Participate in Upcoming AAAAI 2024 Congress - GlobeNewsWire
- 3 months ago - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewsWire
- 5 months ago - Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI) - Benzinga
- 6 months ago - DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers - GlobeNewsWire